Myeloid Leukaemia - Articles and news items

First-in-human trial of MundiPharma’s EDO-S101 starts

Industry news / 14 July 2016 / Victoria White, Digital Content Producer

A first in class, fusion molecule, S101 is currently being developed for the treatment of relapsed-refractory haematological malignances…

NICE says ‘yes ‘ to bosutinib for chronic myeloid leukaemia

Industry news / 7 July 2016 / Victoria White, Digital Content Producer

Bosutinib is the first drug to go through the reappraisal process, where NICE assesses the cost and clinical effectiveness of drugs currently in the old CDF…

First patient treated in fourth dose level NKR-2 Phase I/IIa trial

Industry news / 23 June 2016 / Victoria White, Digital Content Producer

The study is evaluating Celyad’s NKR-2 T-cell therapy using T-cells with NKG2D receptor in patients suffering from AML or multiple myeloma…

Positive interim review in ongoing AML WT1 T cell clinical trial

Industry news / 14 April 2016 / Victoria White, Digital Content Producer

The Cell and Gene Therapy Catapult has announced a positive interim review of a Phase I/II trial using WT1-TCR t-cell therapy to target acute myeloid leukaemia…

FDA grants orphan drug designation to Iomab-B

Industry news / 31 March 2016 / Victoria White

Actinium’s Iomab-B is a radioimmunotherapeutic that conditions relapsed and refractory AML patients for a haematopoietic stem cell transplant…

Celyad posts an update on its NKR-2 Trial

Industry news / 30 March 2016 / Victoria White

Celyad has announced the completion of the safety follow-up of the first patient in the third dose level in the Phase I/IIa of its NKR-2 T-cell therapy…

FDA grants Breakthrough Therapy status to PKC412 (midostaurin)

Industry news / 19 February 2016 / Victoria White

PKC412 (midostaurin) is an investigational treatment for adults with newly-diagnosed acute myeloid leukaemia who are FLT3 mutation-positive…

FDA grants third venetoclax Breakthrough Therapy Designation

Industry news / 28 January 2016 / Victoria White

The designation is for venetoclax in combination with HMAs for the treatment of patients with untreated AML who are ineligible to receive standard induction therapy…

AML treatment market to reach $932.6 million by 2024

Industry news / 9 December 2015 / Victoria White

The treatment market for acute myeloid leukaemia (AML) will rapidly expand in value from $342.7 million in 2014 to reach $932.6 million by 2024, says research and consulting firm GlobalData.

Astellas announces updated results for gilteritinib in AML

Industry news / 7 December 2015 / Victoria White

This updated analysis of the Phase 1/2 study included 169 patients with FLT3 mutations who were treated with at least 80 mg gilteritinib (ASP2215)…

EC approves Vidaza as a new treatment for elderly patients with AML

Industry news / 30 October 2015 / Victoria White

Dr Hervé Dombret says the ‘announcement brings hope to patients with AML, particularly the elderly and more frail patients who cannot undergo intensive therapies’…

First patient dosed in Phase 3 trial of gilteritinib in AML

Industry news / 28 October 2015 / Victoria White

Gilteritinib has demonstrated inhibitory activity against FLT3 internal tandem duplication as well as tyrosine kinase domain, two common types of FLT3 mutations that are seen in AML…

  • Page 1 of 2
  • 1
  • 2
  • >


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...